Masimo Corp Stock Price, News & Analysis

Masimo (NASDAQ: MASI) highlights the findings from a recent whitepaper by the Society for the Advancement of Patient Blood Management (SABM), advocating for continuous hemoglobin (Hgb) monitoring to enhance patient care in critical settings. The whitepaper cites more than a decade of research and emphasizes that real-time Hgb data aids clinicians in making timely decisions, ultimately improving outcomes, reducing blood transfusions, and decreasing costs. Continuous monitoring can lead to significant reductions in post-surgery mortality rates across multiple countries.

Masimo (NASDAQ: MASI) published a study in the Turkish Journal of Emergency Medicine, highlighting the correlation between the Pleth Variability Index (PVi) and volume changes in hemodialysis patients. Conducted by researchers at Kecioren Training and Research Hospital, the study involved 60 patients and demonstrated that PVi increased significantly after fluid removal, indicating its potential for monitoring volume status in critically ill patients. While PVi shows promise, its accuracy in predicting fluid responsiveness can be variable and should not solely drive fluid management decisions.

Masimo (NASDAQ: MASI) announced findings from a study published in the Journal of Pain & Relief, showing that its product Masimo Bridge® significantly reduces postoperative opioid requirements and pain in kidney donor surgery patients. Conducted by researchers at the University of Pittsburgh, the study found a 75.4% reduction in opioid use and 58.3% reduction in pain levels at 24 hours post-surgery for patients using Bridge. The researchers highlighted the potential of this non-invasive device to help combat opioid dependence amid an ongoing opioid crisis.

Masimo reported its Q2 2021 financial results, with product revenue rising 1.4% to $305.1 million. However, the constant currency basis showed a slight decline of 0.1%. The GAAP operating margin improved to 21.3%, while non-GAAP operating margin increased to 23.4%. Net income stood at $50.2 million or $0.88 per diluted share, compared to $55.8 million or $0.96 in Q2 2020. For 2021, the company updated its full-year revenue guidance to $1.216 billion, reflecting a 6.3% growth.

Masimo (NASDAQ: MASI) is set to release its second quarter 2021 financial results on July 27, 2021, after market close. The results will be discussed in a conference call at 1:30 p.m. PT, led by CEO Joe Kiani and CFO Micah Young. Participants can register for the call via a provided link to receive dial-in details. Masimo specializes in medical technology, focusing on innovative monitoring solutions that improve patient outcomes. Its Masimo SET® technology has been validated in over 100 studies, showcasing its effectiveness in clinical settings.

Masimo (NASDAQ: MASI) has released findings from a study in the Journal of Critical Care showing that two parameters from Masimo SedLine^®—Patient State Index (PSi) and Suppression Ratio (SR)—can accurately predict neurological outcomes and long-term survival in post-cardiac arrest ICU patients. The study indicates that low values of PSi and SR correlate with higher mortality rates at 180 days, establishing their effectiveness as prognostic tools. This may influence treatment plans and care decisions in critical care settings.

Masimo (NASDAQ: MASI) has received FDA 510(k) clearance for its Radius Tº™, a wearable thermometer for continuous, noninvasive body temperature monitoring. Suitable for patients aged five and older, it features Bluetooth connectivity for easy integration with Masimo's monitoring solutions and smartphone applications. The device supports hospital automation and streamlines workflows with its single-patient use design. Radius Tº offers enhanced accuracy compared to traditional thermometers, providing critical temperature data for both clinicians and consumers. This clearance marks a significant expansion in Masimo's temperature monitoring capabilities.

Masimo (NASDAQ: MASI) announced a study in the Turkish Journal of Medical Sciences demonstrating that the Oxygen Reserve Index (ORi) can guide oxygenation during one-lung ventilation (OLV) in thoracic surgery. Conducted on 103 patients, the study concluded that ORi-guided oxygen titration might reduce hospital stays and enhance patient safety by minimizing hyperoxic conditions. Findings indicated a significantly shorter duration of OLV and lower FiO₂ values in ORi-monitored groups. ORi, however, is not yet FDA-cleared for use in the U.S.

Masimo (NASDAQ: MASI) announced its management will participate in the UBS Global Healthcare Virtual Conference on May 26, 2021, at 2:00 p.m. Eastern Time. A live webcast will be accessible on the Masimo website, with a replay available afterward.

Masimo is a global medical technology company specializing in advanced monitoring systems and solutions aimed at improving patient outcomes and reducing healthcare costs. Its innovative technologies, including Masimo SET^®, are widely used in hospitals globally, showcasing significant advantages over traditional methods.